CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 26,656	$ 52,418
Marketable securities - short-term	19,554	39,192
Accounts receivable from collaboration	0	944
Prepaid expenses and other current assets	3,462	4,413
Total current assets	49,672	96,967
Property and equipment, net	561	743
Operating lease right-of-use (ROU) assets	844	3,195
Other assets	552	889
Total assets	51,629	101,794
Current liabilities
Accounts payable	758	2,493
Accrued research and development expenses	1,619	3,122
Other accrued expenses	3,886	7,317
Operating lease liabilities - short-term	869	3,364
Total current liabilities	7,132	16,296
Deferred revenue	2,733	2,733
Operating lease liabilities - long-term	50	101
Total liabilities	9,915	19,130
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 52,614,194 and 48,894,973 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	53	49
Additional paid-in capital	816,722	807,938
Accumulated other comprehensive loss	(275)	(803)
Accumulated deficit	(774,786)	(724,520)
Total stockholders' equity	41,714	82,664
Total liabilities and stockholders' equity	$ 51,629	$ 101,794

Accrued research and development expenses current.

No definition available.

Name:	asmb_AccruedResearchAndDevelopmentExpensesCurrent
Namespace Prefix:	asmb_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).